Research & Development
Perrigo reports US FDA approval & upcoming launch of store brand cough control equivalent of Mucinex DM Maximum Strength
8 March 2018 -

Healthcare company Perrigo Company plc (NYSE:PRGO)(TASE:PRGO) reported on Wednesday the receipt of final approval from the US Food & Drug administration for the store brand OTC equivalent of Mucinex DM Maximum Strength (Guaifenesin and Dextromethorphan Hydrobromide Extended-Release Tablets, 1200 mg/60 mg).

The company said the store brand OTC equivalent will be packaged and marketed as a store brand or retailer 'own label' brand and will provide consumers with a high-quality, value alternative to Mucinex DM Maximum Strength.

According to the company, the Mucinex DM Maximum Strength is indicated to control coughs and to break up mucus, making coughs more productive.

Following the US FDA approval, the company is finalising plans to launch its wholly owned store brand equivalent of Mucinex DM Maximum Strength for the 2018 cough-cold season.

For the last 12 months, the retail sales of Mucinex DM Maximum Strength were about USD128m as measured by IRI, concluded the company.

Login
Username:

Password:


Related Headlines